Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT04623242

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease

Sponsor: Accelerating Medicines Partnership (AMP)

Conditions Alzheimers Disease Alzheimers Disease, Familial Dementia

Interventions Gantenerumab Matching Placebo (Gantenerumab) Matching Placebo (Solanezumab) Solanezumab

Updated 7 times since 2020 Last updated: Aug 25, 2022 Started: Dec 31, 2012 Primary completion: Nov 22, 2019 Completion: Mar 6, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04623242, this PHASE2/PHASE3 trial focuses on Alzheimers Disease and Alzheimers Disease, Familial and remains completed. Sponsored by Accelerating Medicines Partnership (AMP), it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Sep 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Apr 2022 — Sep 2022 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2_PHASE3
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Accelerating Medicines Partnership (AMP)
Alzheimer's Association
Avid Radiopharmaceuticals
Eli Lilly and Company
Hoffmann-La Roche
National Institute on Aging (NIA)
Washington University School of Medicine

Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Birmingham, United States , Bron, France , Dublin, Ireland , Indianapolis, United States , La Jolla, United States , Lille, France , London, United Kingdom , Melbourne, Australia and 15 more locations